Targeting SSTR2 with the miniaturized drug conjugate PEN-221 leads to cell-cycle arrest and apoptosis, resulting in tumor regression in multiple SCLC SSTR2-expressing human xenograft models [116]. This evidence concerns the gene SSTR2 and neoplasm.